Video Experimental Relacionado
Updated: Jan 31, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025
Ingeniería de vesículas extracelulares con respuesta a estímulos para mejorar las terapias anticancerígenas
Brian I Molina Diaz1, Pei Zhuang1, Xiaoshu Pan1
1Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA.
Abstract:
Extracellular vesicles (EVs), so called nano-sized vesicles shedding out from cells, have emerged as promising nanocarriers for cancer therapy given their high biocompatibility and low immunogenicity. However, their clinical utility remains limited by challenges such as off-target, premature drug release, and rapid clearance. In solid tumors, these issues are further compounded by the hostile biomechanical environment, including stiff extracellular matrix (ECM), elevated interstitial fluid pressure (IFP), and abnormal vasculatures, further complicates drug delivery and therapeutic efficacy. To overcome these limitations, recent efforts have focused on engineering stimuli-responsive EVs that respond to internal stimuli (e.g., pH, enzymatic activity, redox imbalance) or external stimuli (e.g., magnetic fields, light, ultrasound, temperature), as well as combinations thereof. These smart nanoplatforms have demonstrated a superior capacity in achieving controlled drug release, enhancing tumor targeting, and improving deep tissue penetration. In this minireview, we highlight how stimuli-responsive EVs surpass tumor biomechanics for cancer therapy and discuss key considerations for future development and clinical translation.
Videos de Conceptos Relacionados
Humoral Immune Responses
What is Genetic Engineering?
The Extracellular Matrix
Therapeutic Index
Self-Evaluation: Self-Enhancement and Self-Verification
Bioavailability Enhancement: Drug Solubility Enhancement

